Product Overview
[Drug Name]
Generic Name: Olmesartan Medoxomil Hydrochlorothiazide Tablets
Trade Name: AnAoLan Olmesartan Medoxomil Hydrochlorothiazide Tablets 20/12.5mg * 7 Tablets
Pinyin Full Code: AnAoLan AoMeiShaTanZuoQingLvZuoZuoPian 20/12.5mg * 7 Tablets
[Main Ingredients]
This product is a fixed-dose combination preparation. Each tablet contains 20mg of olmesartan medoxomil and 12.5mg of hydrochlorothiazide.
[Properties]
Olmesartan Medoxomil Hydrochlorothiazide Tablets are film-coated tablets that appear white after removal of the coating.
[Indications/Main Functions]
Indicated for the treatment of hypertension. This product is a fixed-dose combination preparation and is not suitable for the initial treatment of hypertension.
[Specifications]
20/12.5mg*7 tablets
[Dosage and Administration]
For olmesartan medoxomil as monotherapy in normovolemic patients, the recommended starting dose is 20 mg once daily. For patients who require further blood pressure lowering after two weeks of treatment, the dose can be increased to 40 mg. Doses greater than 40 mg have not been shown to provide a greater antihypertensive effect. When the daily dose is the same, twice-daily dosing has not been shown to provide superiority compared to once-daily dosing. No starting dose adjustment is required for elderly patients, patients with moderate to significant renal impairment (creatinine clearance <40 mL/minute), or patients with moderate to significant hepatic impairment (see Special Populations in Pharmacokinetics). Treatment with this drug must be initiated under close medical supervision in patients with potential volume depletion (e.g., those receiving diuretics, particularly those with renal impairment), and a lower starting dose may be considered (see [Precautions]: Hypotension in Patients with Volume Depletion or Hyponatremia). The effective dose of hydrochlorothiazide is 12.5-50 mg once daily. Olmesartan medoxomil or hydrochlorothiazide monotherapy is typically initiated after unsatisfactory efficacy has been achieved with monotherapy with olmesartan medoxomil or hydrochlorothiazide. This product is taken orally, one tablet once daily. Dosage should be individualized. Based on the antihypertensive effect, the dose can be adjusted at intervals of 2-4 weeks. The antihypertensive effect of this product is dose-dependent within the dose range of 10mg/12.5mg to 40mg/25mg. Olmesartan medoxomil and hydrochlorothiazide tablets exhibit a hypotensive effect within 1 week, reaching maximum hypotensive effect after 4 weeks. This product can be used in combination with other antihypertensive medications. If the patient's creatinine clearance is >30mL/min, the standard dose of this product can be used. In patients with more severe renal impairment, myeloid diuretics are preferred over thiazide diuretics, and therefore this product is not recommended. No dose adjustment is required in patients with hepatic impairment (see Special Populations in [Pharmacokinetics]).
[Adverse Reactions]
See package insert for details.
